- Home
- ACRV vs REAL Comparison
ACRV vs REAL Comparison
Compare ACRV & REAL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACRV
- REAL
- Stock Information
- Founded
- ACRV 2018
- REAL 2011
- Country
- ACRV United States
- REAL United States
- Employees
- ACRV N/A
- REAL N/A
- Industry
- ACRV Medicinal Chemicals and Botanical Products
- REAL Other Specialty Stores
- Sector
- ACRV Health Care
- REAL Consumer Discretionary
- Exchange
- ACRV Nasdaq
- REAL Nasdaq
- Market Cap
- ACRV 247.8M
- REAL 295.1M
- IPO Year
- ACRV 2022
- REAL 2019
- Fundamental
- Price
- ACRV $8.04
- REAL $4.06
- Analyst Decision
- ACRV Strong Buy
- REAL Buy
- Analyst Count
- ACRV 5
- REAL 7
- Target Price
- ACRV $22.40
- REAL $3.89
- AVG Volume (30 Days)
- ACRV 44.7K
- REAL 2.5M
- Earning Date
- ACRV 11-13-2024
- REAL 11-04-2024
- Dividend Yield
- ACRV N/A
- REAL N/A
- EPS Growth
- ACRV N/A
- REAL N/A
- EPS
- ACRV N/A
- REAL N/A
- Revenue
- ACRV N/A
- REAL $579,862,000.00
- Revenue This Year
- ACRV N/A
- REAL $10.55
- Revenue Next Year
- ACRV N/A
- REAL $8.32
- P/E Ratio
- ACRV N/A
- REAL N/A
- Revenue Growth
- ACRV N/A
- REAL 2.52
- 52 Week Low
- ACRV $3.19
- REAL $1.52
- 52 Week High
- ACRV $11.90
- REAL $4.64
- Technical
- Relative Strength Index (RSI)
- ACRV 48.60
- REAL 73.51
- Support Level
- ACRV $7.69
- REAL $3.63
- Resistance Level
- ACRV $8.54
- REAL $4.27
- Average True Range (ATR)
- ACRV 0.34
- REAL 0.25
- MACD
- ACRV -0.03
- REAL 0.09
- Stochastic Oscillator
- ACRV 23.59
- REAL 86.22
About ACRV Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.
About REAL The RealReal Inc.
The RealReal is the largest pure-play luxury resale platform in the us, generating $1.7 billion in 2023 gross merchandise volume and addressing a niche (personal luxury resale) that had previously been serviced by inefficient upscale boutiques and local pawn shops. The company generates revenue via consignment and first-party sales on its online marketplace, and through a small volume of direct sales. With a hands-on approach that actively sources inventory and authenticates every item on its platform, The RealReal is able to justify much higher take rates than peers, working out to roughly 34% of net merchandise value, which excludes returns, cancellations, and first-party sales.